Turkish Journal of Medical Sciences
Volume 38

Number 3

Article 15

1-1-2008

Gastrointestinal Stromal Tumor with Pulmonary Metastasis
AHMET GÜRER
SELMA GÖĞKUŞ
BÜLENT DEMİRBAŞ
EREN ERSOY
RACİ AYDIN

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
GÜRER, AHMET; GÖĞKUŞ, SELMA; DEMİRBAŞ, BÜLENT; ERSOY, EREN; and AYDIN, RACİ (2008)
"Gastrointestinal Stromal Tumor with Pulmonary Metastasis," Turkish Journal of Medical Sciences: Vol.
38: No. 3, Article 15. Available at: https://journals.tubitak.gov.tr/medical/vol38/iss3/15

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

CASE REPORT

Ahmet GÜRER1
Selma GÖ⁄KUﬁ1
Bülent DEM‹RBAﬁ1
Eren ERSOY2
Raci AYDIN1

Turk J Med Sci
2008; 38 (3): 273-275
© TÜB‹TAK
E-mail: medsci@tubitak.gov.tr

Gastrointestinal Stromal Tumor with Pulmonary
Metastasis
Abstract: Gastrointestinal stromal tumor (GIST) is rare but is the most common mesenchymal tumor of the
gastrointestinal tract. It is usually arises from the stomach and small intestine. We present a case of GIST
treated with surgery and adjuvant imatinib mesylate for pulmonary metastasis.
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Akci¤erlere Metastaz Yapm›ﬂ Gastrointestinal Stromal Tümör
Özet: Gastrointestinal stromal tümörler (GIST) nadir görülmesine karﬂ›n gastrointestinal sistemin en s›k
gözlenen mezenkimal tümörleridir. Biz burada cerrahi ve pulmoner metastazlar› için de adjuvan imatinib
mesilat tedavisi uygulanan GIST olgusunu sunmaktay›z.
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Introduction
Stromal tumors are the most common mesenchymal tumors of the gastrointestinal
tract, although they are very rare (1). They usually arise from the stomach or small
intestine and the primary therapeutic approach is surgery. Imatinib mesylate, a specific
tyrosine kinase inhibitor, is gaining increasing popularity for adjuvant chemotherapy as
GIST therapy is a good sample for molecular cancer treatment modalities. Imatinib
mesylate is also effective in patients who have metastases.
Here we report a case of jejunal GIST, with multiple pulmonary metastases.
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A 75-year-old male was admitted to our clinic with a 3-month history of an
abdominal mass. By this time the patient had lost 5-6 kg but the gastrointestinal passage
was not problematic. His physical examination revealed an abdominal mass of 20 × 15
cm along the right hypochondriac and lumbar regions. In abdominal ultrasonography the
palpated mass showed a hypo-echoic, heterogeneous, and vascularized structure that
caused significant thickening in the intestinal wall. In addition, it caused compression on
the aorta and vena cava inferior according to endoscopic ultrasonography. In contrast
abdominal computerized tomography an intra-abdominal mass of 20 × 10 × 12 cm was
detected, which was highly contrasted and showed a relationship with a jejunal segment
(Figure 1). After that mesenteric angiography was performed to determine probable
vascular invasion but no invasion was detected. Because of the suspicious images
fluorodeoxyglucose positron emission tomography was performed and multiple lesions
of metastasis were detected in the lungs (Figure 2). In conclusion, the probable diagnosis
decided on was metastatic gastrointestinal stromal tumor. The tumor, originating from
the jejunum, was resected and no vascular invasion was detected (Figure 3). GIST and
CD 117 were highly positive in the immunohistochemical evaluation (Figure 4). The
patient had no complications after the operation and chemotherapy was scheduled.
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Figure 1. Intraperitoneal mass, with necrosis in center.

Figure 2. Pulmonary increased FDG activation.

Figure 3. Fragile mass originating from jejunum.

Figure 4. Spherical or spindle-shaped differentiated cells with clear
cytoplasm that show strong activation of CD 117 (×40).

Discussion
Gastrointestinal stromal tumors (GISTs) originate
from Cajal’s intestinal cells, which are known to be the
pacemakers of intestinal myenteric plexus and considered
to be a different entity to sarcomas (2). Kinase inhibitor
of thyrosine (KIT) (CD 117) is detected
immunohistochemically in most gastrointestinal stromal
tumor cases (3,4). Although GISTs are known to be
sporadic, there are families reported to have germline
mutation in KIT (5). GISTs usually become symptomatic
when they reach large diameters and symptoms are due
to bleeding or obstruction. Computerized tomography
and magnetic resonance imaging are valid for evaluating
both primary tumors and metastatic lesions. FDG-PET
274
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has high sensitivity but low specificity for GISTs.
Moreover, it is a valuable tool for evaluating therapeutic
progress. Percutaneous biopsy may be used in the
differential diagnosis when the lesion is easy to
manipulate without serious complications.
The primary therapeutic approach is surgery for
GISTs. It is possible to excise the lesion with negative
surgical borders in most cases but no beneficial effect of
lymphatic resection has been proved (6). The effect of
postoperative imatinib mesylate is controversial for
resections with tumor free surgical borders but it seems
beneficial for locally advanced or metastatic disease (1).
Mitotic index and the diameter of the tumor are regarded
as the most important prognostic criteria for a GIST (7).
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In addition, GIST may show associations with other
malignancies and this is also a determinant for prognosis
(8). The follow-up schedule for a GIST larger than 5 cm
or having more than 5 mitoses in flow cytometry is every
3 months for the first 3 years and every 6 months for the
following 2 years by computerized tomography. Smaller
or less mitotic lesions should be followed up every 6
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months for 5 years (9).. In a retrospective study of 200
GIST patients who only had surgical therapy, Ronald et al.
stated that 47% showed metastasis while 7% showed
local recurrence and the overall 5-year surveillance was
54% (10). The literature about GIST patients who had
chemotherapy including imatinib mesylate or other
agents is still insufficient.
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